Calculate exact reconstitution volumes, insulin units, and doses per vial for any peptide.
N-Acetyl Semax is a chemically modified variant of the neuropeptide Semax. The parent molecule, Semax, is a synthetic heptapeptide of seven amino acids with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), derived from a fragment of the adrenocorticotropic hormone (ACTH 4-10). In N-Acetyl Semax, the N-terminus of the molecule carries an additional acetyl group. This small but functionally significant modification alters the peptide's pharmacokinetic profile without abolishing its core neurotropic properties. N-Acetyl Semax is therefore classified as a pure research neuropeptide rather than a hormone, since it too lacks the corticotropic, adrenal-stimulating activity of the original ACTH fragment.
The purpose of the acetylation is to increase stability against peptidases. Peptides are broken down rapidly in the body by enzymes that typically attack free N-termini. By blocking that attack point with an acetyl group, N-Acetyl Semax becomes more resistant to enzymatic degradation. In research practice, N-Acetyl Semax is therefore frequently described as a more potent and longer-acting version of Semax. Like the parent peptide, it is administered almost exclusively intranasally — as an aqueous solution in the form of nasal drops or nasal spray — and not by injection.
N-Acetyl Semax comes from the same Russian research tradition as Semax, which was developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences together with Lomonosov Moscow State University. The acetylated variant was later designed as an attempt to extend the short duration of action of the parent peptide. An important distinction: while Semax has a limited clinical use history in Russia, the data available for N-Acetyl Semax is predominantly preclinical and pharmacological in nature. Large-scale human studies are lacking, which is why all use remains within a research context.
N-Acetyl Semax shares the fundamental activity profile of Semax, modulating several neurochemical systems simultaneously rather than acting through a single receptor. The mechanisms best documented in preclinical research are:
An important distinction from classic stimulants: N-Acetyl Semax does not acutely raise catecholamine release in the manner of an amphetamine but instead modulates signal processing. The reported effects are therefore better described as regulating and stabilizing rather than acutely activating. As with Semax, the biological duration of action is decoupled from the very short plasma half-life, since downstream signaling cascades remain detectable for hours after administration.
Because N-Acetyl Semax is administered intranasally, dosing does not refer to an injection volume but to the amount of peptide delivered into the nose per application. The lyophilized powder is typically dissolved in water so that a defined concentration per drop is produced. Because the acetylated variant is regarded as more potent, protocols often begin at the lower end of the dosing range and are increased cautiously only when needed.
A common vial size is 5 mg. Dissolving it in 2 mL of a suitable solvent (sterile or bacteriostatic water) gives a concentration of 2.5 mg/mL (2,500 mcg/mL). A typical drop from a standard dropper bottle is approximately 0.05 mL.
Exact drop size varies by pipette or spray head, so it is only a guide. At a daily dose of 300 mcg, a 5 mg vial mathematically lasts about 16 days. Use the N-Acetyl Semax calculator above to determine concentration, volume per dose, and how long a vial lasts for any vial size and solvent volume.
N-Acetyl Semax is supplied as a lyophilized (freeze-dried) powder in sealed vials and must be brought into solution before use. For an intranasal solution used over several days, bacteriostatic water is sensible because the benzyl alcohol it contains inhibits microbial growth. Cleanliness is especially important when working with the nasal mucosa, since a contaminated solution repeatedly contacts sensitive tissue.
Before use, gently blow the nose if needed. Tilt the head slightly back or to the side and deliver the calculated number of drops per nostril, without letting the pipette or spray head touch the nasal mucosa. After instillation, remain in the tilted position for a few seconds so the solution can be absorbed by the mucosa, and do not blow the nose immediately afterward. If the daily dose is split, the applications should be spread sensibly across the first half of the day, since the drive-oriented effect can disrupt sleep in the evening. If the solution is cloudy, discolored, or contains visible particulate matter, discard the vial and do not continue to use it.
N-Acetyl Semax, like the parent peptide Semax, is regarded as well tolerated in preclinical research. Because the corticotropic activity profile of the original ACTH fragment is not retained in the molecule, N-Acetyl Semax does not stimulate the adrenal axis and causes no hormonal shifts. However, robust long-term human data is lacking, which is why use remains in the research domain. Since the acetylated variant is described as more potent, observations that occur in a dose-dependent manner with Semax may be more pronounced at a comparable amount.
No serious adverse events have been described in the published research at standard doses. Given the absence of large-scale international studies, caution is warranted and consultation with a qualified healthcare provider is strongly recommended.
In practice, N-Acetyl Semax is usually not used together with Semax but is considered an alternative to it. Both share the same mechanism of action through the upregulation of neurotrophic factors, but the acetylation gives N-Acetyl Semax greater stability and a longer duration of action. Anyone switching from Semax to N-Acetyl Semax should recalibrate the dose, since the effective potency differs. Using both compounds simultaneously offers no clear added benefit from a mechanistic standpoint, as they act on the same signaling pathways.
A combination common in research practice is N-Acetyl Semax with Selank. Both peptides come from the same Russian research tradition and are administered intranasally, but they complement each other in profile: N-Acetyl Semax is more drive- and focus-oriented, while Selank, as an anxiolytic peptide, contributes a calming, anxiety-dampening component. In combination, the stack aims to support cognitive performance without the jitteriness often associated with stimulants. The two solutions are typically prepared separately and applied one after the other, not mixed in a single vial.
Some research protocols combine N-Acetyl Semax used during the day with DSIP (Delta Sleep-Inducing Peptide) in the evening. The idea is to confine the drive-oriented effect of N-Acetyl Semax to the active part of the day and flank it with a sleep-supporting component in the evening. Because N-Acetyl Semax can disrupt sleep when used late, this temporal separation directly addresses the timing problem.
N-Acetyl Semax carries an acetyl group at the N-terminus that makes the molecule more stable against enzymatic degradation. As a result, N-Acetyl Semax tends to act more strongly and for longer than unmodified Semax. Both share the same mechanism of action through the upregulation of neurotrophic factors such as BDNF and NGF. Anyone switching between the two compounds should adjust the dose, as the effective potency is not identical.
N-Acetyl Semax is used almost universally as nasal drops or nasal spray. The nasal mucosa is highly vascularized, and a portion of the peptide can reach central nervous structures comparatively directly via the olfactory nerve. The intranasal route also bypasses the first-pass metabolism of the liver. Because peptides of the Semax family are broken down very quickly in plasma, mucosal absorption offers a practical, non-invasive route of administration.
Users frequently report a relatively rapid effect on alertness and concentration within the first one to two hours after application. Due to the stability extended by acetylation, the noticeable phase is tended to be described as longer-lasting than with Semax. The neurotrophic effects — the upregulation of BDNF and NGF — develop more slowly and are associated with repeated application over several days and weeks.
No. Although the Semax family is derived from an ACTH fragment, the structural modification removes the corticotropic, hormone-stimulating activity. N-Acetyl Semax does not stimulate the adrenal glands and does not raise cortisol levels. It is therefore classified as a pure neuropeptide rather than a hormone; no post-cycle therapy is required.
In research practice, N-Acetyl Semax is frequently described as the more potent and longer-acting variant, which is attributed to the stability against peptidases increased by the acetyl group. This does not mean a higher dose is needed; on the contrary, a more pronounced effect is expected at a comparable amount. For this reason, a cautious start at the lower end of the dosing range is advisable.
Research protocols often run for two to four weeks, followed by a break. Longer continuous use is described, but cyclical application is preferred as a precaution since robust long-term human data is lacking. Breaks also provide the opportunity to assess one's actual baseline state without the peptide.
It can. Because of its drive- and alertness-oriented effect, N-Acetyl Semax can make it harder to fall asleep when used in the late afternoon or evening. In practice, application is therefore usually placed in the first half of the day. If a daily dose is split, the final application should not be too late.
No. N-Acetyl Semax does not acutely raise catecholamine release in the manner of a classic stimulant but instead modulates signal processing in monoaminergic and neurotrophic systems. The reported effects are better described as regulating and stabilizing. A pronounced crash effect like that seen with stimulants is typically not reported.
Medical Disclaimer: The information on this page is provided for educational and research purposes only. N-Acetyl Semax is not an approved drug or medical treatment and is sold strictly for research use. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. BergdorfBio assumes no liability for the use or misuse of the information presented here.